Compare EPR Properties (EPR) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPR Properties vs Sanofi SA — how do they compare? EPR Properties trades at $54.8 (market cap $4.17B), while Sanofi SA trades at $40.16 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 22.8× EPR Properties's market cap, and EPR Properties pays the higher dividend (6.84%). Which is the better fit depends on your goals — on Pluang, investors hold EPR Properties for 45 Days and Sanofi SA for 94 Days on average.
| EPR | SNY | |
|---|---|---|
Market Cap | $4.17B | $95.18B |
Volume | 992,716 | 2,995,646 |
Sector | Real Estate | Health |
52-Week High | $64.32 | $52.34 |
52-Week Low | $48.71 | $39.51 |
Typical Hold Time | 45 Days | 94 Days |
Enterprise Value | $7.68B | $114.48B |
Dividend Yield | 6.84% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPR Properties trades at $54.49, up 0.76% today, with a bearish technical signal but oversold oscillators suggesting potential reversal. The REIT shows strong profitability with a 37.66% net income margin and a 6.5% dividend yield, though earnings have been mixed with a recent miss in Q1 2026. Analysts maintain a consensus Buy rating with a $65.50 price target, implying significant upside from current levels.
The outlook is cautiously optimistic given the high dividend yield and discounted valuation, but risks include exposure to interest rate sensitivity and tenant performance in its experiential real estate portfolio. Near-term catalysts include the Q3 2026 earnings release on October 28, 2026, which could validate the company's growth trajectory amid a challenging macro environment.
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
